Press release
2019-03-13
Xbrane Biopharma & Vator Securities invites to company presentations regarding the ongoing rights issue. Date and time for the presentations are,
- Friday 15 March, at 11:30
- Monday 18 March, at 17:30
- Tuesday 19 March, at 11:30
- Tuesday 19 March, at 17:30
The presentations will be held at T-House, Engelbrektsplan 1, Stockholm.
Xbrane Biopharma will be represented by Martin Åmark, CEO.
To attend the events, a registration is needed. Registration are made by following the link.
Xbrane Biopharma will also conduct the following presentations,
- Biostock Live, Wednesday 20 March between 10.00-13.00
The slot time for Xbrane is not yet decided and the registration for the event opens at Friday, 15 of March. Registration to the event is made through BioStock web page. The event will take place at Nyhetsbyrån Direkt office at Kungsgatan 33, Stockholm.
- Vator Securities Unicorn Summit, Thursday 21 March
The event is fully booked.
About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long-acting injectables. Xbrane has world leading expertise in developing generics for long-acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser. For more information see www.xbrane.com.
For further information, please contact:
Martin Åmark
CEO / IR
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com
Susanna Helgesen
CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com
